HeartBeam Commences Underwritten Public Offering of Common Stock
HeartBeam announced that it is commencing an underwritten public offering of shares of its common stock. All of the securities to be sold in the proposed offering will be offered by HeartBeam. The company intends to use the net proceeds from this offering to advance commercialization of its FDA-cleared 12-lead synthesized ECG system, advance development of its extended-wear patch and heart attack detection initiatives, further enhance its AI capabilities, and for working capital and general corporate purposes. Titan Partners, a division of American Capital Partners, is acting as the sole bookrunner for the proposed offering.
